About Beryllium

OUR MISSION.

Our mission is to provide best-in-class lead discovery solutions.  Our proven teams of drug discovery professionals are passionate about unlocking the therapeutic potential of both genetically- and clinically-validated drug targets, and in developing new therapeutic modalities. We work in partnership with our clients to address the most difficult scientific and business challenges facing drug discovery, and to ultimately enable transformational health care outcomes.

A MARKET IN FLUX.

All levels of the research-based pharmaceutical industry is in the midst of significant change as economic, regulatory and scientific challenges dictate the efficiencies of drug discovery. Large pharmaceutical companies are seeking ways to enhance the quantity and quality of their pipelines with less risk.  Smaller companies are developing lean/virtual models that are based on focused, therapeutic development, while academic and institutional research organizations are mitigating a decrease in government funding by attempting to develop commercial partnerships to offset the drop in traditional funding.

AN OPPORTUNITY TO MAKE A DIFFERENCE.

The progression from invention to innovation (i.e. discovery) is being affected by these changes. Beryllium is uniquely positioned to serve the needs of this evolving landscape. Moreover, we have a successful track record in pursuing targets that have not been drugged before, opening the door to both genetically- and clinically-validated targets, and developing new therapeutic modalities. We are enabling novel drug discovery by marrying world-class structural and functional biology-centric platforms with drug discovery process expertise. Our goal is to deliver validated starting points that improve the success of drug development programs and most importantly- make a difference to patients.

BERYLLIUM’S PARTNERSHIPS

At Beryllium, we are applying our scientific and program management expertise to our collaborations. We believe that a true understanding of the underlying biology is the basis of a successful drug discovery program. We are focused on building partnerships and collaborations around our research platforms to address the most difficult scientific and business challenges facing the industry.

Senior Leadership Team

Prior to co-founding Beryllium in 2009 I co-founded Pod Holding Ltd (Pod Investment) in 2000 and served as its Managing Partner until 2008. During my 8 years at Pod I served as lead partner on investment activities for a number of companies, including the cancer company, Pintex Pharmaceuticals and the anti-infectives company Paratek Pharmaceuticals (PRTK)…Read More

I started working at MediChem Life Sciences, a drug discovery and technology company, in a finance role when I graduated from college. deCODE Genetics acquired MediChem three years later, and I stayed on as vice president of finance at the Icelandic company’s U.S. office. Later, I became chief financial officer of Emerald Bio when the company spun out from deCODE in 2009…Read More

As head of research, I utilize my expertise from my time in academia, big pharma, biotech startups and my own consulting firm to lay the groundwork for our company’s future drug discovery methods and breakthroughs. Before joining Beryllium, I founded ALN Associates, a life sciences consultancy…Read More

Senior Management Team

With over a decade of industry expertise, I have been at the forefront of numerous, successful structure determination research collaborations, including hepatitis C virus (HCV), oncology and diabetes targets. Prior to joining Beryllium, I was a crystallographer and senior research scientist at the Seattle Structural Genomics Center for Infectious Disease (SSGCID)…Read More

I began my career in the biotech industry in 1995 and it has included positions at Thermo Fisher and Lonza Biologics. I earned my Bachelor’s degree from Old Dominion University. As a Navy spouse I had the opportunity to live all over the world from Italy to Hawaii to Washington State…Read More

Justin Boyd, Ph.D.

I bring to Beryllium over a decade of research experience in phenotypic profiling, especially in neurobiology. As an entrepreneurial scientist, I am accomplished in the fields of neuroscience, stem cell biology, and drug discovery. The challenge that I hope to address is creating innovation and improved efficiency in drug discovery…Read More

I have been working with an interdisciplinary team to build and strengthen fragment-based discovery at Beryllium for ten years. I worked as the project lead on the effort to build our first in-house fragment screening collection, the metabolome-influenced “Fragments of Life.” …Read More

JOHAN PONTIN

Chairman & CEO

BRENT BANNERMAN

Entrepreneur and Independent Investor

JEFF NEWTON, M.B.A.

Managing Director at Gemini Investors

Jeff Newton has been a managing director of Gemini Investors since 1997 and an active participant in the private equity market since 1992. He has played a lead role in more than 40 transactions and has represented Gemini on the board of directors of more than 20 portfolio companies, including on Beryllium’s board since 2009.

Prior to joining Gemini, Jeff was president of Concord Partners Ltd., a middle-market investment banking firm that advised privately-held companies on merger and acquisition transactions. Previously, he served as a senior vice president and treasurer of Lifetime Corporation, which at the time, was the largest home health care services company in the U.S. and before that, as a vice president in the investment banking division at Prudential Securities. Jeff is a member of the M.B.A. board of advisors at the Tuck School. Jeff holds a bachelor’s degree from the University of Vermont and a Master of Business Administration from Dartmouth College.

NEIL WEIR, Ph.D.

Senior Vice President of Discovery at UCB

Dr. Neil Weir leads discovery at UCB, where he oversees an integrated portfolio of small-molecule and antibody therapeutic projects in the areas of immunology and neurology. Neil and his discovery team have transitioned 20 novel molecules from discovery into development. His research interests during 25 years in the biopharmaceutical industry have included antibody engineering and expression and modification of antibodies in the fields of drug conjugates, half-life modification and gene therapy; he is one of the inventors of the antibody fragment-based drug, Cimzia®. Neil joined Beryllium’s board in 2014.

Neil is also a member of the Research Directors Group of EFPIA (European Federation of Pharmaceutical Industries and Associations) and has sponsored three call topics in the European Innovative Medicines Initiative (IMI). He currently serves as chair of the Association of the British Pharmaceutical Industry (ABPI) innovation board. He has a bachelor’s degree with honors in biology from Edinburgh University and a doctorate in at the University of Kent at Canterbury’s Institute of Biotechnology studying metabolic flux through amino acid biosynthesis pathways.

SUE R. WINDHAM-BANNISTER, Ph.D.

Vice Chair, Tufts Health Plan

Managing Partner, Biomedical Innovation Advisors LLC

Dr. Susan Windham-Bannister is a nationally and internationally recognized innovation expert. She was recognized by the Boston Globe as one of the “10 Most Influential Women in Biotech” in 2013. Dr. Windham-Bannister currently serves as Managing Partner of Biomedical Innovation Advisors LLC, which she founded with Dr. Harvey Lodish, co-founder of Genzyme and a member of the Whitehead Institute, MIT. She also serves as the President and CEO of Biomedical Growth Strategies, LLC. Both of these advisory firms leverage Dr. Windham-Bannister’s experience as the immediate past President and CEO of the Massachusetts Life Sciences Center (MLSC), a state-funded investment organization charged with administering the $1-billion Life Sciences fund that was proposed by Governor Deval Patrick in 2007 and signed into law in June 2008. The MLSC is the hub for all sectors of the Commonwealth’s life sciences community – biotechnology, pharmaceuticals, medical devices, medical diagnostics and bioinformatics.

During her tenure as the founding executive of the MLSC, Dr. Windham-Bannister was responsible for the overall implementation of the Life Sciences Initiative, including formulating the investment strategy for the $1B fund, staffing and managing the organization, developing policies and procedures and building national and international partnerships. The MLSC’s portfolio of investments is promoting economic development, catalyzing innovation, strengthening Massachusetts’ global leadership position in the life sciences, and accelerating the commercialization of promising treatments, therapies and cures.

@2016 Beryllium Discovery Corp – 844-BE4-FOUR | info@be4.com

Terms of Services º Terms of Use